

Cadila Pharma unveils ground-breaking iron injection to treat anaemia

19 March 2024 | News

Redshot Injection stands out as an intravenous iron preparation that delivers effective amounts of iron



Ahmedabad-based Cadila Pharmaceuticals has announced the launch of a novel iron injection, a next-generation solution for addressing iron deficiency anaemia. The product will be available as **Redshot FCM**, fortified with the advanced **Ferric Carboxymallose formulation**, designed for administration to both adults and paediatric patients over one year of age, especially those with oral iron intolerance.

Redshot Injection stands out as an intravenous iron preparation that not only delivers effective amounts of iron but also boasts an exemplary safety profile. With superior tolerability and minimal to zero risk of anaphylaxis, Redshot accelerates the improvement of haemoglobin levels and efficiently replenishes depleted iron stores. Offering heightened tolerability, the intravenous delivery of iron in Redshot facilitates the utilization of high doses in a single administration.

Anaemia, characterised by impaired physical activities, general weakness, lethargy, and fatigue, often goes unnoticed and is inadequately managed, particularly in pregnancy, the elderly population, and cancer patients. Remarkably, Redshot addresses this gap, as anaemia is prevalent in cancer patients and has been linked to lower survival rates for those grappling with this deficiency. Anaemia in pregnancy, if not treated, can complicate childbirth and can put mothers and neonates at serious risks.